Orchid Biosciences Sells SNPstream System to British Co., Makes Equity Investment | GenomeWeb

NEW YORK, Oct. 1 – Orchid BioSciences said Monday it had sold its SNPstream system for SNP scoring to Tepnel Life Sciences and made an equity investment in the Manchester, UK-based company.

Under the terms of the deal, Tepnel will also gain access to Orchid’s SNP databases and biochemistry and software kits. In exchange Orchid has acquired the option to evaluate some of Tepnel’s discoveries for possible commercialization.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.